Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Crosses Below 50-Day Moving Average – Here’s Why

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) crossed below its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $15.46 and traded as low as $14.99. Ascentage Pharma Group International shares last traded at $15.00, with a volume of 7,313 shares.

Analysts Set New Price Targets

Several research firms have recently commented on AAPG. BTIG Research reaffirmed a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. William Blair began coverage on Ascentage Pharma Group International in a research report on Friday, October 16th. They issued an “outperform” rating for the company. JPMorgan Chase & Co. lowered their price objective on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a research report on Thursday, October 8th. Citizens Jmp began coverage on Ascentage Pharma Group International in a research note on Tuesday, October 13th. They set a “market outperform” rating and a $35.00 target price for the company. Finally, Citigroup initiated coverage on Ascentage Pharma Group International in a research report on Wednesday, October 14th. They issued a “buy” rating and a $46.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating and eleven have given a Buy rating to the company’s stock. According to MarketBeat.com, Ascentage Pharma Group International currently has an average rating of “Buy” and an average target price of $43.44.

Ascentage Pharma Group International Stock Performance

The stock’s 50-day simple moving average is $15.36 and its 200 day simple moving average is $19.61. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The business had revenue of $22.24 million for the quarter. As a group, analysts predict that Ascentage Pharma Group International – Unsponsored ADR will post -2.43 EPS for the current fiscal year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company’s two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.